Chimeric enters strategic manufacturing partnership with WuXi Advanced Therapies
April 11, 2022 23:00 ET | Chimeric Therapeutics Limited
MELBOURNE, Australia, April 11, 2022 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX:CHM, “Chimeric”) a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to...
Chimeric Transforms Portfolio With a Clinically Validated, Off the Shelf, Natural Killer (NK) Cell Platform
November 30, 2021 20:54 ET | Chimeric Therapeutics Limited
Chimeric has obtained the exclusive option to license the CORE-NK platform, a Clinically validated, Off the shelf, Robust, Enhanced Natural Killer cell platform from Case Western Reserve University...